Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Criteria for choosing clinically effective glaucoma treatment: A discussion panel consensus</title><author><name sortKey="Thygesen, John" sort="Thygesen, John" uniqKey="Thygesen J" first="John" last="Thygesen">John Thygesen</name><affiliation><nlm:aff id="aff1">Department of Ophthalmology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark</nlm:aff></affiliation></author><author><name sortKey="Burk, Reinhard" sort="Burk, Reinhard" uniqKey="Burk R" first="Reinhard" last="Burk">Reinhard Burk</name><affiliation><nlm:aff id="aff2">Department of Ophthalmology, Academic Hospital Bielefeld, Bielefeld, Germany</nlm:aff></affiliation></author><author><name sortKey="Carassa, Roberto" sort="Carassa, Roberto" uniqKey="Carassa R" first="Roberto" last="Carassa">Roberto Carassa</name><affiliation><nlm:aff id="aff3">Department of Ophthalmology and Visual Sciences, San Raffaele Hospital, Milan, Italy</nlm:aff></affiliation></author><author><name sortKey="Crichton, Andrew" sort="Crichton, Andrew" uniqKey="Crichton A" first="Andrew" last="Crichton">Andrew Crichton</name><affiliation><nlm:aff id="aff4">Department of Surgery, University of Calgary, Calgary, Alberta, Canada</nlm:aff></affiliation></author><author><name sortKey="Go I, Francisco Javier" sort="Go I, Francisco Javier" uniqKey="Go I F" first="Francisco Javier" last="Go I">Francisco Javier Go I</name><affiliation><nlm:aff id="aff5">Institut de Microcirurgia Ocular (IMO), Universidad Autonoma de Barcelona, Barcelona, Spain</nlm:aff></affiliation></author><author><name sortKey="Menage, Mitch" sort="Menage, Mitch" uniqKey="Menage M" first="Mitch" last="Menage">Mitch Menage</name><affiliation><nlm:aff id="aff6">Leeds General Infirmary, Leeds, United Kingdom</nlm:aff></affiliation></author><author><name sortKey="Miglior, Stefano" sort="Miglior, Stefano" uniqKey="Miglior S" first="Stefano" last="Miglior">Stefano Miglior</name><affiliation><nlm:aff id="aff7">University of Milan Bicocca, Milan, Italy</nlm:aff></affiliation></author><author><name sortKey="Montgomery, Donald" sort="Montgomery, Donald" uniqKey="Montgomery D" first="Donald" last="Montgomery">Donald Montgomery</name><affiliation><nlm:aff id="aff8">Eye Department, Glasgow Royal Infirmary, Glasgow, United Kingdom</nlm:aff></affiliation></author><author><name sortKey="Nordmann, John Philippe" sort="Nordmann, John Philippe" uniqKey="Nordmann J" first="John-Philippe" last="Nordmann">John-Philippe Nordmann</name><affiliation><nlm:aff id="aff9">Centre Hospitalier des Quinze-Vingts, Paris, France</nlm:aff></affiliation></author><author><name sortKey="Roberts, Tim" sort="Roberts, Tim" uniqKey="Roberts T" first="Tim" last="Roberts">Tim Roberts</name><affiliation><nlm:aff id="aff10">Department of Ophthalmology, Royal North Shore Hospital, University of Sydney, Sydney, Australia</nlm:aff></affiliation></author><author><name sortKey="Singh, Kuldev" sort="Singh, Kuldev" uniqKey="Singh K" first="Kuldev" last="Singh">Kuldev Singh</name><affiliation><nlm:aff id="aff11">Department of Ophthalmology, Stanford University Medical Center, Stanford, California, USA</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">24683204</idno><idno type="pmc">3967348</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3967348</idno><idno type="RBID">PMC:3967348</idno><idno type="doi">10.1016/j.curtheres.2007.06.002</idno><date when="2007">2007</date><idno type="wicri:Area/Pmc/Corpus">001835</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001835</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Criteria for choosing clinically effective glaucoma treatment: A discussion panel consensus</title><author><name sortKey="Thygesen, John" sort="Thygesen, John" uniqKey="Thygesen J" first="John" last="Thygesen">John Thygesen</name><affiliation><nlm:aff id="aff1">Department of Ophthalmology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark</nlm:aff></affiliation></author><author><name sortKey="Burk, Reinhard" sort="Burk, Reinhard" uniqKey="Burk R" first="Reinhard" last="Burk">Reinhard Burk</name><affiliation><nlm:aff id="aff2">Department of Ophthalmology, Academic Hospital Bielefeld, Bielefeld, Germany</nlm:aff></affiliation></author><author><name sortKey="Carassa, Roberto" sort="Carassa, Roberto" uniqKey="Carassa R" first="Roberto" last="Carassa">Roberto Carassa</name><affiliation><nlm:aff id="aff3">Department of Ophthalmology and Visual Sciences, San Raffaele Hospital, Milan, Italy</nlm:aff></affiliation></author><author><name sortKey="Crichton, Andrew" sort="Crichton, Andrew" uniqKey="Crichton A" first="Andrew" last="Crichton">Andrew Crichton</name><affiliation><nlm:aff id="aff4">Department of Surgery, University of Calgary, Calgary, Alberta, Canada</nlm:aff></affiliation></author><author><name sortKey="Go I, Francisco Javier" sort="Go I, Francisco Javier" uniqKey="Go I F" first="Francisco Javier" last="Go I">Francisco Javier Go I</name><affiliation><nlm:aff id="aff5">Institut de Microcirurgia Ocular (IMO), Universidad Autonoma de Barcelona, Barcelona, Spain</nlm:aff></affiliation></author><author><name sortKey="Menage, Mitch" sort="Menage, Mitch" uniqKey="Menage M" first="Mitch" last="Menage">Mitch Menage</name><affiliation><nlm:aff id="aff6">Leeds General Infirmary, Leeds, United Kingdom</nlm:aff></affiliation></author><author><name sortKey="Miglior, Stefano" sort="Miglior, Stefano" uniqKey="Miglior S" first="Stefano" last="Miglior">Stefano Miglior</name><affiliation><nlm:aff id="aff7">University of Milan Bicocca, Milan, Italy</nlm:aff></affiliation></author><author><name sortKey="Montgomery, Donald" sort="Montgomery, Donald" uniqKey="Montgomery D" first="Donald" last="Montgomery">Donald Montgomery</name><affiliation><nlm:aff id="aff8">Eye Department, Glasgow Royal Infirmary, Glasgow, United Kingdom</nlm:aff></affiliation></author><author><name sortKey="Nordmann, John Philippe" sort="Nordmann, John Philippe" uniqKey="Nordmann J" first="John-Philippe" last="Nordmann">John-Philippe Nordmann</name><affiliation><nlm:aff id="aff9">Centre Hospitalier des Quinze-Vingts, Paris, France</nlm:aff></affiliation></author><author><name sortKey="Roberts, Tim" sort="Roberts, Tim" uniqKey="Roberts T" first="Tim" last="Roberts">Tim Roberts</name><affiliation><nlm:aff id="aff10">Department of Ophthalmology, Royal North Shore Hospital, University of Sydney, Sydney, Australia</nlm:aff></affiliation></author><author><name sortKey="Singh, Kuldev" sort="Singh, Kuldev" uniqKey="Singh K" first="Kuldev" last="Singh">Kuldev Singh</name><affiliation><nlm:aff id="aff11">Department of Ophthalmology, Stanford University Medical Center, Stanford, California, USA</nlm:aff></affiliation></author></analytic><series><title level="j">Current Therapeutic Research, Clinical and Experimental</title><idno type="ISSN">0011-393X</idno><imprint><date when="2007">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><p>Abstract</p></sec><sec><title><bold>Background:</bold></title><p>In the clinical management of patients at risk for or diagnosed with primary open-angle glaucoma (POAG), the aim of medical treatment is to reduce intraocular pressure (IOP) and then maintain it over time at a level that preserves both the structure and function of the optic nerve.</p></sec><sec><title><bold>Objective:</bold></title><p>The objective of this report was to establish a consensus on the criteria that should be used to determine the characteristics of IOP-lowering medication.</p></sec><sec><title><bold>Methods:</bold></title><p>Discussion was held among a panel of 12 physicians considered to be experts in glaucoma to develop a consensus on the criteria used by them to determine the characteristics of the IOP-lowering medication chosen for initial monotherapy and adjunctive treatment of ocular hypertension (OHT) or POAG. Consensus development combined available evidence and the impressions of these physicians regarding the clinical effectiveness of IOP-lowering medication for OHT and POAG. Once the panel identified the criteria, the order of priority and the relative importance of these criteria were then established in the setting of 3 risk categories (low, medium, and high) for a patient to experience significant visual disability from glaucoma over their expected life span.</p></sec><sec><title><bold>Results:</bold></title><p>The panel identified 5 criteria to determine the characteristics of IOP-lowering medication for OHT and POAG: IOP-lowering effect, systemic adverse events (AEs), ocular tolerability, compliance/administration, and cost of treatment. IOP-lowering effect was consistently ranked as the highest priority and cost as the lowest. The priority of compliance/administration did not vary by clinical situation. Systemic AEs and ocular tolerability were ranked as higher priorities in initial monotherapy than in adjunctive treatment and ranked lower as the risk for visual disability increased. The priority given to the criteria used to determine clinical effectiveness varied both with the risk for functional vision loss from glaucoma and whether initial monotherapy or adjunctive treatment was being considered.</p></sec><sec><title><bold>Conclusion:</bold></title><p>Glaucoma treatment should be assessed with regard to the need not only to lower IOP but also to minimize systemic and ocular AEs, promote patient compliance, and minimize cost. The order of priority and relative importance given to these treatment criteria will vary as part of individualizing patient care.</p></sec></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Ther Res Clin Exp</journal-id><journal-id journal-id-type="iso-abbrev">Curr Ther Res Clin Exp</journal-id><journal-title-group><journal-title>Current Therapeutic Research, Clinical and Experimental</journal-title></journal-title-group><issn pub-type="ppub">0011-393X</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24683204</article-id><article-id pub-id-type="pmc">3967348</article-id><article-id pub-id-type="publisher-id">S0011-393X(07)00049-5</article-id><article-id pub-id-type="doi">10.1016/j.curtheres.2007.06.002</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Criteria for choosing clinically effective glaucoma treatment: A discussion panel consensus</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Thygesen</surname><given-names>John</given-names></name><degrees>MD</degrees><email>john.thygesen@rh.hosp.dk</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="cor1" ref-type="corresp">12</xref></contrib><contrib contrib-type="author"><name><surname>Burk</surname><given-names>Reinhard</given-names></name><degrees>MD</degrees><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Carassa</surname><given-names>Roberto</given-names></name><degrees>MD</degrees><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Crichton</surname><given-names>Andrew</given-names></name><degrees>MD</degrees><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Goñi</surname><given-names>Francisco Javier</given-names></name><degrees>MD</degrees><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Menage</surname><given-names>Mitch</given-names></name><degrees>MD</degrees><xref rid="aff6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name><surname>Miglior</surname><given-names>Stefano</given-names></name><degrees>MD</degrees><xref rid="aff7" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name><surname>Montgomery</surname><given-names>Donald</given-names></name><degrees>MD</degrees><xref rid="aff8" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name><surname>Nordmann</surname><given-names>John-Philippe</given-names></name><degrees>MD</degrees><xref rid="aff9" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><name><surname>Roberts</surname><given-names>Tim</given-names></name><degrees>MD</degrees><xref rid="aff10" ref-type="aff">10</xref></contrib><contrib contrib-type="author"><name><surname>Singh</surname><given-names>Kuldev</given-names></name><degrees>MD</degrees><xref rid="aff11" ref-type="aff">11</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Ophthalmology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark</aff><aff id="aff2"><label>2</label>Department of Ophthalmology, Academic Hospital Bielefeld, Bielefeld, Germany</aff><aff id="aff3"><label>3</label>Department of Ophthalmology and Visual Sciences, San Raffaele Hospital, Milan, Italy</aff><aff id="aff4"><label>4</label>Department of Surgery, University of Calgary, Calgary, Alberta, Canada</aff><aff id="aff5"><label>5</label>Institut de Microcirurgia Ocular (IMO), Universidad Autonoma de Barcelona, Barcelona, Spain</aff><aff id="aff6"><label>6</label>Leeds General Infirmary, Leeds, United Kingdom</aff><aff id="aff7"><label>7</label>University of Milan Bicocca, Milan, Italy</aff><aff id="aff8"><label>8</label>Eye Department, Glasgow Royal Infirmary, Glasgow, United Kingdom</aff><aff id="aff9"><label>9</label>Centre Hospitalier des Quinze-Vingts, Paris, France</aff><aff id="aff10"><label>10</label>Department of Ophthalmology, Royal North Shore Hospital, University of Sydney, Sydney, Australia</aff><aff id="aff11"><label>11</label>Department of Ophthalmology, Stanford University Medical Center, Stanford, California, USA</aff><author-notes><corresp id="cor1"><label>12</label><bold>Address correspondence to:</bold> John Thygesen, MD, Associate Professor, Department of Ophthalmology 2061, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. <email>john.thygesen@rh.hosp.dk</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>1</day><month>5</month><year>2007</year></pub-date><pmc-comment> PMC Release delay is 0 months and 0 days and was based on .</pmc-comment>
<pub-date pub-type="ppub"><month>5</month><year>2007</year></pub-date><volume>68</volume><issue>3</issue><fpage>127</fpage><lpage>136</lpage><history><date date-type="accepted"><day>26</day><month>4</month><year>2007</year></date></history><permissions><copyright-statement>© 2007 The Authors. Published by Elsevier Inc. All rights reserved.</copyright-statement><copyright-year>2007</copyright-year><copyright-holder>Excerpta Medica, Inc. All rights reserved</copyright-holder></permissions><abstract><sec><p>Abstract</p></sec><sec><title><bold>Background:</bold></title><p>In the clinical management of patients at risk for or diagnosed with primary open-angle glaucoma (POAG), the aim of medical treatment is to reduce intraocular pressure (IOP) and then maintain it over time at a level that preserves both the structure and function of the optic nerve.</p></sec><sec><title><bold>Objective:</bold></title><p>The objective of this report was to establish a consensus on the criteria that should be used to determine the characteristics of IOP-lowering medication.</p></sec><sec><title><bold>Methods:</bold></title><p>Discussion was held among a panel of 12 physicians considered to be experts in glaucoma to develop a consensus on the criteria used by them to determine the characteristics of the IOP-lowering medication chosen for initial monotherapy and adjunctive treatment of ocular hypertension (OHT) or POAG. Consensus development combined available evidence and the impressions of these physicians regarding the clinical effectiveness of IOP-lowering medication for OHT and POAG. Once the panel identified the criteria, the order of priority and the relative importance of these criteria were then established in the setting of 3 risk categories (low, medium, and high) for a patient to experience significant visual disability from glaucoma over their expected life span.</p></sec><sec><title><bold>Results:</bold></title><p>The panel identified 5 criteria to determine the characteristics of IOP-lowering medication for OHT and POAG: IOP-lowering effect, systemic adverse events (AEs), ocular tolerability, compliance/administration, and cost of treatment. IOP-lowering effect was consistently ranked as the highest priority and cost as the lowest. The priority of compliance/administration did not vary by clinical situation. Systemic AEs and ocular tolerability were ranked as higher priorities in initial monotherapy than in adjunctive treatment and ranked lower as the risk for visual disability increased. The priority given to the criteria used to determine clinical effectiveness varied both with the risk for functional vision loss from glaucoma and whether initial monotherapy or adjunctive treatment was being considered.</p></sec><sec><title><bold>Conclusion:</bold></title><p>Glaucoma treatment should be assessed with regard to the need not only to lower IOP but also to minimize systemic and ocular AEs, promote patient compliance, and minimize cost. The order of priority and relative importance given to these treatment criteria will vary as part of individualizing patient care.</p></sec></abstract><kwd-group><title>Key Words</title><kwd>consensus</kwd><kwd>criteria</kwd><kwd>intraocular pressure</kwd><kwd>glaucoma</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 0018359 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 0018359 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |